Results 151 to 160 of about 777,778 (283)
ICU‐EEG Pattern Detection by a Convolutional Neural Network
ABSTRACT Objective Patients in the intensive care unit (ICU) often require continuous EEG (cEEG) monitoring due to the high risk of seizures and rhythmic and periodic patterns (RPPs). However, interpreting cEEG in real time is resource‐intensive and heavily relies on specialized expertise, which is not always available.
Giulio Degano+5 more
wiley +1 more source
Special Issue "Molecules at Play in Neurological Diseases". [PDF]
Iacobas DA.
europepmc +1 more source
Animal Models of Neurological Disease [PDF]
openaire +2 more sources
Long‐Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons
ABSTRACT Objectives This ongoing, open‐label extension study is evaluating the long‐term safety, tolerability, and efficacy of givinostat, a Class I and II histone deacetylase inhibitor, in patients with Duchenne muscular dystrophy (DMD). Methods The recruited patients completed one of two prior clinical studies (one Phase 2 and one Phase 3 [EPIDYS ...
Craig M. McDonald+74 more
wiley +1 more source
Experimental Evidence on Acupuncture Targeting Ferroptosis for Neurological Function Improvement in Cerebral Stroke: A Systematic Review and Meta-Analysis. [PDF]
Zhang W+7 more
europepmc +1 more source
Annals of Clinical and Translational Neurology, EarlyView.
Majid Khalilizad+4 more
wiley +1 more source
ABSTRACT Objective Recurrent high‐grade gliomas have a poor prognosis and limited therapeutic options. This study aimed to evaluate the safety and efficacy of SYHA1813, a dual inhibitor of VEGFR and CSF1R, in patients with recurrent high‐grade gliomas.
Zhuang Kang+16 more
wiley +1 more source
Mouse models of neurological disorders
openaire +2 more sources
Protein production is an early biomarker for RNA‐targeted therapies [PDF]
Alex, Jacob+10 more
core +2 more sources
Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis
ABSTRACT Objective We report the 12‐month follow‐up outcomes from a Phase 2 clinical trial (NCT04146051) evaluating Descartes‐08, a BCMA‐directed RNA chimeric antigen receptor T‐cell (rCAR‐T) therapy for refractory generalized myasthenia gravis (MG).
Nizar Chahin+10 more
wiley +1 more source